The Patented Medicines Prices Review Board (PMPRB) has published its Administrative Process for Excessive Price Hearing Recommendation (effective January 2026) after years of consultation. From the announcement, “The new Guidelines explain the new two-step process used by PMPRB staff to monitor and review drug prices by comparing the prices in other countries or to other similar treatments in Canada.”